![外围股市大涨,A股如何开工?大摩透露上调中国股票估值原因](https://i-invdn-com.investing.com/news/LYNXNPEAB10I3_S.jpg)
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
代码 | 交易平台 | 货币 | ||
---|---|---|---|---|
AMGN | 纳斯达克 | USD | 实时 | |
AMGN | BIVA | MXN | 延迟 | |
AMGN | 墨西哥 | MXN | 延迟 | |
AAMGN | 米兰 | EUR | 实时 | |
AMGN | TradeGate | EUR | 延迟 | |
AMGN | 德国法兰克福 | EUR | 延迟 | |
AMGN | 法兰克福 | EUR | 延迟 | |
AMGN | 阿根廷 | ARS | 延迟 | |
AMGN34 | B3 | BRL | 延迟 | |
4332 | 香港 | HKD | 延迟 | |
AMGN | 奥地利维也纳 | EUR | 实时 |
安进公司是一家生物技术公司。该公司探索、开发、制造及销售人类治疗药品。该公司通过人类治疗药品业务运营。该公司销售的药品包括:Neulasta(pegfilgrastim),Aranesp(darbepoetin alfa)及EPOGEN(epoetin alfa)等促红细胞生成剂,Sensipar/Mimpara(cinacalcet),XGEVA(denosumab),Prolia(denosumab),NEUPOGEN(filgrastim),和Vectibix (panitumumab)、Nplate(romiplostim)及Corlanor(ivabradine)等。该公司专注于研发用于治疗肿瘤及血液病、心血管病、炎症、骨骼病、肾脏病及神经疾病等严重疾病的人类药物。该公司研发的处于第III阶段的产品包括用于发作性偏头痛的Erenumab,骨髓增生异常综合征的Aranesp,急性淋巴细胞白血病的BLINCYTO和转移性黑色素瘤的IMLYGIC。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Robert A. Eckert | 69 | 2012 | Lead Independent Director |
Greg C. Garland | 66 | 2013 | Independent Director |
Tyler E. Jacks | 62 | 2012 | Independent Director |
Brian J. Druker | 68 | 2018 | Independent Director |
Ellen J. Kullman | 67 | 2016 | Independent Director |
David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
Wanda M. Austin | 69 | 2017 | Independent Director |
Amy E. Miles | 56 | 2020 | Independent Director |
S. Omar Ishrak | 67 | 2021 | Independent Director |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Ronald D. Sugar | 74 | 2010 | Independent Director |
R. Sanders Williams | 74 | 2014 | Independent Director |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Charles M. Holley | 66 | 2017 | Independent Director |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Michael V. Drake | 72 | 2022 | Independent Director |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Robert Tjian | 74 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Frank P. McCormick | 73 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Ronald M. Evans | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
George Georgiou | 64 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Peter Libby | 76 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Antoni Ribas | 57 | - | Member of Scientific Advisory Board of Oncology |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核